5% discount on your next human biospecimen order from
Tissue For Research when you forward proof of purchase of animal-free recombinant antibodies.
There are many advantages to using recombinant antibodies, as outlined in the latest ECVAM publication.
The following is a non-exhaustive list of some of the companies and organizations providing such ethical reagents;
Aptagen is a leading world-wide biotechnology company offering aptamer (synthetic antibody) products and services as research reagents, diagnostic and biomarker discovery tools, as well as for use in drug discovery and targeted delivery for therapeutics, and bioindustrial applications. We have a combined 25+ years of experience in creating aptamers that bind a wide variety of targets against small molecules, proteins, biomarkers and cells. Aptagen has performed this service for more than 50 companies, organizations, and institutions worldwide.
Absolute Antibody provides Antibody Sequencing, Engineering & Recombinant Expression
Abcalis produces monoclonal, multiclonal and polyclonal antibodies.
AvantGen has constructed 30 human antibody libraries (Germliner™) with multiple human antibody germline frameworks. These were selected based on their high stability, solubility and expression level. Diversity is focused in the CDR regions and mimics the diversity of the natural human antibody repertoire for that variable region family. The framework sequences are left as fully human germline sequences. AvantGen’s proprietary libraries are comprised of >100 billion members, are well expressed and displayed with AvantGen’s yeast display system allowing efficient human antibody discovery.
Providing recombinant antibodies to the academic community, not-for-profit.
One of the few laboratories in the world that produces fully-human, full-length, antigen-specific antibodies for use in studying human immune responses. The Core has achieved breakthroughs in antibody technology and has produced hundreds of high affinity protective antibodies to influenza, anthrax lethal toxin, and various S. pneumonia polysaccharides. The Core aims to support investigators by helping quantify the antibody secreting cell responses after vaccination and by generating human monoclonal antibodies to be characterized. Pathogen-specific human monoclonal antibodies are also available for licensing agreements and other forms of commercial development.
Drug-like antibodies from selections.
YUMAB provides individually designed contract research projects for the discovery and the development of fully human antibodies, as well as R&D services for the engineering of antibodies.